Make your money go further for just 25p per day

Advanced Medical Solutions (AIM:AMS) FDA approval enhances the appeal

03/11/2015 · Advanced Medical Solutions (AMS) 

The surgical and advanced woundcare company and one of AIM’s star performers has announced that the FDA has approved two new product claims for the Group’s product. The news moved the shares up another leg to new highs.

The FDA has approved two new product claims for the Group’s octyl formulation product, LiquiBand Exceed™ giving it a competitive advantage in the topical skin adhesive market.

The two new claims include the use of a single device to cover wounds of up to 30cm, as well as a single device being suitable for intraoperative reuse for up to 90 minutes on a single patient. Both…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Advanced Medical Solutions

Healthcare advances | Quality in video gaming

19/09/2024 · Company Insights

News covered here includes our assessment of results from a company operating in the healthcare sector.…


Odd name but great results | Director buying | Retailer woes

17/07/2024 · Company Insights

News covered here includes our assessment of excellent results from a provider of a diverse range…


More Company Insights

AIM new arrivals and departures October 2024

08/11/2024 · GenIP · Pulsar Helium

Challenging outlooks | Reassuringly boring | Hidden value

Stonking Small Cap reports cracking results

06/11/2024 · dotDigital

Sign-up to our free email updates

SIGN UP